Page 85 - Human Use News Today

21st Austria weekly - Uniqa Valneva 02/03/2023 [pic1]Uniqa: The international ratings agency Standard & Poor’s S&P upgraded the outlook for Uniqa Insurance Group AG Österreich Versicherungen AG and UniqaRe from “negative” to “stable”. S&P also reconfirmed “A” rating UNIQA

21st Austria weekly - Uniqa Valneva 02/03/2023 [pic1]Uniqa: The international ratings agency Standard & Poor’s S&P upgraded the outlook for Uniqa Insurance Group AG Österreich Versicherungen AG and UniqaRe from “negative” to “stable”. S&P also reconfirmed “A” rating UNIQA

21st Austria weekly - Uniqa Valneva 02/03/2023 [pic1]Uniqa: The international ratings agency Standard & Poor’s S&P upgraded the outlook for Uniqa Insurance Group AG Österreich Versicherungen AG and UniqaRe from “negative” to “stable”. S&P also reconfirmed “A” rating UNIQA

21st Austria weekly - Uniqa Valneva 02/03/2023 [pic1]Uniqa: The international ratings agency Standard & Poor’s S&P upgraded the outlook for Uniqa Insurance Group AG Österreich Versicherungen AG and UniqaRe from “negative” to “stable”. S&P also reconfirmed “A” rating UNIQA

European Medicines Agency has issued a positive opinion for the use of VLA2001 among certain adults - News - PharmaTimes

In its latest meeting, the CHMP recommended eight new medicines for approval, including an enzyme replacement therapy for a rare disease.

The Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the oral androgen receptor inhibitor (ARi) darolutamide plus ADT in combination with docetaxel in the indication of metastatic prostate cancer. The MHLW approval is based on the positive results from the Phase III ARASENS trial, which ...

The antiviral pill could not demonstrate benefits in treatment of Covid patients.

The positive CHMP opinion for upadacitinib is based on results from two induction studies and one maintenance study1-4 Crohns disease is a chronic, systemic...

The European Unions drug regulator said on Friday its Committee for Medicinal Products for Human Use has advised against market authorisation of the COVID-19 pill from Merck for treatment in adults.